Innate Pharma Files 6-K, Announces Press Release
Ticker: IPHYF · Form: 6-K · Filed: Apr 28, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Apr 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, press-release
TL;DR
Innate Pharma dropped a 6-K on 4/28/25 with a press release - check that for news.
AI Summary
Innate Pharma SA filed a Form 6-K on April 28, 2025, reporting a press release dated the same day. The filing does not contain specific financial figures or operational updates beyond the announcement of the press release itself.
Why It Matters
This filing indicates Innate Pharma is making a public announcement, which could contain material information for investors. Investors should review the referenced press release for details.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a press release and does not contain new financial or operational information that would inherently increase risk.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- April 28, 2025 (date) — Filing date and press release date
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report a press release issued by Innate Pharma SA on April 28, 2025.
What is the filing date of this Form 6-K?
The Form 6-K was filed on April 28, 2025.
Does this filing include financial statements?
No, this Form 6-K filing does not include financial statements; it primarily serves to attach a press release.
What is the Commission File Number for Innate Pharma SA?
The Commission File Number for Innate Pharma SA is 001-39084.
Where is Innate Pharma SA's principal executive office located?
Innate Pharma SA's principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 28, 2025 regarding Innate Pharma SA (IPHYF).